Figure 3From: Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)HDJ-2 gel shift in peripheral blood lymphocytes analyzed ex vivo. PBMCs obtained pre-treatment and during week 7 of therapy were analyzed by Western blot for the apparent molecular weight of the farnesylated protein HDJ-2. The appearance of a higher molecular weight band is indicative of a non-farnesylated state.Back to article page